TIME StudyHypertension Treatment in Morning versus Evening Objective:To determine whether evening dosing of antihypertensive medication improves major cardiovascular outcomes compared to morning dosing in patients with hypertension. Study Design: Participants: Primary Endpoint: Results: Conclusion:Evening dosing of antihypertensive medication did not … Read More
hypertension
ATHENA-HF Trial: High-Dose Spironolactone in Acute Heart Failure
The ATHENA-HF trial, published in JAMA Cardiology in 2017, evaluated the efficacy and safety of high-dose spironolactone in patients with acute heart failure (AHF). This was a double-blind, placebo-controlled randomized clinical trial, aiming to assess whether high-dose spironolactone could significantly … Read More
AMBER Trial: Patiromer to Allow Spironolactone use in Resistant Hypertension
Resistant hypertension poses a significant challenge, especially in patients with chronic kidney disease (CKD). The AMBER trial emerges as a beacon of hope, evaluating the role of the potassium binder patiromer in enabling the use of spironolactone in this difficult-to-treat … Read More
Landmark Clinical Trials of Aldosterone Antagonists
landmark clinical trials focusing on aldosterone antagonists (mineralocorticoid receptor antagonists) like spironolactone and eplerenone, which are commonly used in heart failure and other conditions: 1. RALES (1999) • Title: Randomized Aldactone Evaluation Study • Focus: Heart failure with reduced ejection … Read More
VERONICA-Nigeria Trial: Triple-Pill for Hypertension
The VERONICA-Nigeria trial, published in JAMA in 2024, evaluated the efficacy and safety of a low-dose triple-pill protocol (telmisartan, amlodipine, and indapamide) versus a standard-care protocol for managing hypertension in Black African adults. This parallel-group, open-label, randomized controlled trial involved … Read More
Target-HTN trial: Lorundrostat in Hypertension
The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More
RADIANCE-HTN TRIO Trial: Renal Denervation in HTN
The RADIANCE-HTN TRIO trial, detailed in The Lancet in 2021, is another pivotal study in the domain of hypertension treatment, focusing on a challenging group of patients: those resistant to a standard triple combination pill. This trial delves into the … Read More
RADIANCE-HTN SOLO Trial: Renal Denervation in HTN
The RADIANCE-HTN SOLO trial, published in The Lancet in May 2018, marks a significant stride in hypertension treatment research. This trial focused on the safety and efficacy of a novel endovascular ultrasound renal denervation procedure compared to a sham procedure … Read More
DCP Trial Summary: HCTZ vs Chlorthalidone
2022 DCP TRIAL Chlorthalidone compared with hydrochlorothiazide for the preven- tion of cardiovascular events in patients with hypertension: The Diuretic Comparison Project (DCP) Open-label, pragmatic, randomized controlled trial Objective: To compare the differences between hydrochlorothiazide (HCTZ) compared with chlorthalidone in … Read More
TIME Trial Summary: Morning vs. Evening dose of Antihypertensives
2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication … Read More